C12N 2710/24021
Viruses as such
Official title: Viruses as such, e.g. new isolates, mutants or their genomic sequences
C12N2710/24021 (Viruses as such) appears on 15 US grants and 30 published applications in this corpus.
Search patents in C12N- Granted patents
- 15
- Published applications
- 30
- Assignees
- 22
- Inventors
- 53
- Latest grant
- 2 Jun 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1997 | 1 | 0 |
| 1998 | 0 | 0 |
| 1999 | 0 | 0 |
| 2000 | 0 | 0 |
| 2001 | 0 | 0 |
| 2002 | 0 | 0 |
| 2003 | 0 | 0 |
| 2004 | 0 | 0 |
| 2005 | 0 | 0 |
| 2006 | 0 | 0 |
| 2007 | 0 | 0 |
| 2008 | 0 | 0 |
| 2009 | 0 | 2 |
| 2010 | 0 | 0 |
| 2011 | 0 | 0 |
| 2012 | 0 | 0 |
| 2013 | 0 | 0 |
| 2014 | 0 | 0 |
| 2015 | 0 | 3 |
| 2016 | 0 | 3 |
| 2017 | 1 | 2 |
| 2018 | 0 | 3 |
| 2019 | 1 | 1 |
| 2020 | 1 | 3 |
| 2021 | 2 | 3 |
| 2022 | 2 | 2 |
| 2023 | 0 | 1 |
| 2024 | 3 | 1 |
| 2025 | 2 | 3 |
| 2026 | 2 | 3 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Compositions and methods for inducing an enhanced immune response using poxvirus vectors2 Jun 2026US 12,644,125 B2Bavarian Nordic A/S
- Non-invasive agent applicator13 Jan 2026US 12,521,540 B2MuPharma Pty Ltd
- Oncolytic virus expressing a car T cell target and uses thereof22 Jul 2025US 12,364,724 B2City of Hope
- Synthetic chimeric poxviruses22 Jul 2025US 12,365,879 B2Tonix Pharma Limited
- Myxoma virus compositions and methods of use29 Oct 2024US 12,128,099 B2BioVentures, LLC
- Synthetic chimeric poxviruses21 May 2026US 2026/0139233 A1Tonix Pharma Limited
- Chimeric poxviruses19 Feb 2026US 2026/0049291 A1Transgene S. A.
- Synthetic chimeric poxviruses22 Jan 2026US 2026/0022350 A1Tonix Pharma Limited
- Oncolytic virus expressing a car t cell target and uses thereof18 Dec 2025US 2025/0381237 A1City of Hope
- Cancer therapies comprising a nuclear export inhibitor and an oncolytic virus7 Aug 2025US 2025/0249056 A1Arizona Board of Regents on behalf of Arizona State University
Most cited
By later US patents
- Recombinant fowlpox virus23US 5,670,367 AImmuno Aktiengesellschaft · 1997
- Fusion polypeptides and vaccines1US 10,174,084 B2Ceva Sante Animale · 2019
- Poxvirus-Plasmodium recombinants, compositions containing such recombinants, uses thereof, and methods of making and using the same1US 11,168,307 B2V-Core Technologies, Inc. · 2021
- Synthetic chimeric poxviruses1US 11,345,896 B22022
- Synthetic chimeric poxviruses1US 12,365,879 B2Tonix Pharma Limited · 2025